Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Warfarin resistance and related pharmacogenetic information].

Brain and nerve = Shinkei kenkyu no shinpo - 1 Nov 2008

Takahashi Harumi

Abstract excerpt

Warfarin is the mainstay of anticoagulation therapy worldwide. Its clinical use, however, is complicated by the fact that it has a narrow therapeutic index with potential bleeding complications. The dosage requirement of warfarin to produce therapeutic anticoagulation varies widely among patients. Recently genetic factors such as the CYP2C9 and VKORC1 genes have been demonstrated to be determinants of warfarin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Metabolic Clearance Rate

Share to Mixed Function Oxygenases

Share to Pharmacogenetics

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 19069171

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Warfarin resistance and related pharmacogenetic information].PMID 19069171Read ↗

[Effect of genetic variations on adjusting of warfarin dose].Semantic proximity Read ↗

Warfarin PharmacogeneticsSemantic proximity Read ↗

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.Semantic proximity Read ↗

Pharmacogenetics of warfarin: current status and future challenges.Semantic proximity Read ↗

Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotype distribution in Asian countries.Semantic proximity Read ↗

[Genetic and bioenvironmental factors associated with warfarin response in Colombian patients].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.